Meningococcal disease is a leading cause of meningitis and septicaemia globally, most often striking small children and teenagers. Due to the lack of efficient vaccines, serogroup B meningococcal disease is currently emerging on a worldwide basis. The rat ional design of outer membrane protein-based vaccines must take into account the antigenic variability of circulating meningococcal strains to determine the most appropriate epitopes for inclusion in a vaccine. Therefore, new vaccine candidates on the bas is of antigenicity screens, reverse vaccinology and antigen conservation are in demand. An effective vaccine needs to induce protective bactericidal and opsonophagocytic antibodies against one or more cell surface components expressed by the infective age nt, N. meningitidis. In order to prevent endemic as well as epidemic outbreaks, the vaccine should elicit protective antibodies against antigens that are conserved among the wide range of strains responsible for meningococcal infections. The main objectiv e of the project is to identify these antigens among our novel candidates. We have evidence of outer membrane proteins that induce protective antibodies. The long-term goal is to design a new vaccine strategy to prevent meningococcal disease, including en demic serogroup B meningococcal infections.